Inside Health – 15/1/12

On Amitriptyline  – here is the very good information website we talked about

Asthma, eczema and ‘junk food’ study


Here’s the questionnaire as part of the ISAAC studies – lots of information here 

3 Responses to “Inside Health – 15/1/12”

  1. Alan Henness January 17, 2013 at 12:25 am #

    Oh dear.

    The ‘junk food’ study concluded:

    ” If the association between fast foods and the symptom prevalence of asthma, rhinoconjunctivitis and eczema is causal…”

    How What Doctors Don’t Tell You reported it:

    Fast-food increases teenagers’ asthma risk by 40 per cent

    16 January 2013
    Fast-food could be causing asthma, eczema and rhinitis (stuffy and runny nose), researchers claim this week. Children who have three or more servings every week are especially at risk, and their health problems could be more severe.

    Three or more servings of fast-food such as burgers increase the risk for severe asthma by 39 per cent in teenagers and by 27 per cent in younger children.

    Fruit has a protective effect, and a child is less likely to suffer from asthma the more fruit he or she eats.

    Researchers from the International Study of Asthma and Allergies in Childhood (Isaac) said that fast-food has high levels of saturated and trans fatty acids, which affect the immune system, while fruit is rich in antioxidants, which help promote good immune system functioning.

    Their findings are based on surveys of 319,000 teenagers and 181,000 six-year-olds living in up to 51 countries, who were asked about any illnesses and their severity, and the foods they ate. The clearest association was between the immune-responsive diseases such as asthma and eczema and fast-food.

    (Source: Thorax, 2013; doi: 10.1136/thoraxjnl-2012-202285).”

  2. Margaret McCartney
    margaretmccartney January 17, 2013 at 11:35 am #

    why am I not surprised?!?

  3. steve January 20, 2013 at 3:19 pm #

    I don’t know if you saw this…

    Painful Diabetic Neuropathy: A Three-Drug Comparison

    Diabetes Care 2012 Dec; 35:2451. (

    Amitriptyline, duloxetine, and pregabalin reduced pain to a similar extent.

    Head-to-head comparisons of drugs commonly prescribed for painful diabetic neuropathy are scarce. In this double-blind trial, funded by a maker of pregabalin (an anticonvulsant; Lyrica), 83 patients (mean age, 65) with painful diabetic neuropathy were randomized to receive amitriptyline (a tricyclic antidepressant), duloxetine (a serotonin-norepinephrine reuptake inhibitor; Cymbalta), or pregabalin. Patients were treated for 4 weeks; total daily doses were titrated to a maximum of 75 mg of amitriptyline, 120 mg of duloxetine, and 600 mg of pregabalin.

    At 4 weeks, mean pain scores had improved in all three groups, with no significant differences among groups. Duloxetine lessened sleep efficiency compared with the other two drugs, whereas pregabalin was associated with slightly worse cognitive function than the other two drugs. Adverse effects (particularly fatigue, dizziness, and somnolence) were most common with pregabalin. Premature withdrawal from the study due to adverse events occurred in six pregabalin recipients, three duloxetine recipients, and one amitriptyline recipient.

    Comment: These three drugs had similar effects on painful diabetic neuropathy. Pregabalin was the least well tolerated, perhaps because of the high dose (note that target doses for duloxetine and pregabalin in this study were twice that of the FDA-approved maximal doses for diabetic neuropathy). Amitriptyline — by far the least expensive alternative — seems to be the winner here; however, many patients can’t tolerate its anticholinergic side effects, and tricyclics are contraindicated in some patients with cardiac disease.